INBP.US Integrated Biopharma Inc
- Market cap
- USD 5.28M
- P/E
- -
- P/B
- 0.29x
- ROE
- -16.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is INBP.US undervalued?
Graham numberThe Graham number of Integrated Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Integrated Biopharma Inc fundamental analysis
No fundamental analysis for Integrated Biopharma Inc yet.
Integrated Biopharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Integrated Biopharma Inc
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-car…
Full company profileIntegrated Biopharma Inc financial statements
Integrated Biopharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 47.0M | 43.7M | 50.0M | 52.8M | 63.6M | 56.2M | 50.7M | 50.3M | 54.4M | 43.9M |
| Gross Profit | 6.67M | 4.99M | 6.22M | 6.73M | 9.48M | 6.55M | 4.06M | 3.88M | 5.56M | 800K |
| Operating Income | 3.19M | 1.69M | 2.70M | 3.26M | 5.78M | 2.75M | 120K | 251K | 2.02M | -2.71M |
| EBITDA | 3.03M | 2.28M | 3.45M | 4.26M | 8.33M | 3.54M | 1.27M | 1.47M | 3.29M | -1.32M |
| Net Income | 2.35M | 679K | 1.69M | 4.11M | 8.01M | 3.84M | -34.0K | 112K | 808K | -2.84M |
| EPS | 0.11 | 0.03 | 0.06 | 0.14 | 0.27 | 0.13 | 0.00 | 0.00 | 0.03 | -0.09 |
| Balance Sheet | ||||||||||
| Total Assets | 15.2M | 14.6M | 19.8M | 22.9M | 25.4M | 25.3M | 25.4M | 26.2M | 24.9M | 25.3M |
| Total Liabilities | 21.1M | 19.8M | 17.9M | 16.9M | 11.1M | 6.68M | 6.57M | 6.97M | 4.58M | 7.67M |
| Shareholders' Equity | -5.93M | -5.24M | 1.89M | 6.07M | 14.3M | 18.6M | 18.9M | 19.2M | 20.3M | 17.7M |
| Cash & Short-term Investments | 597K | 228K | 475K | 402K | 210K | 331K | 1.32M | 1.68M | 3.62M | 4.47M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 397K | 1.17M | 328K | 1.34M | 3.05M | 4.09M | 1.23M | 943K | 2.07M | 1.24M |
| Capital Expenditure | 327K | 247K | 414K | 214K | 295K | 486K | 116K | 553K | 205K | 346K |
| Free Cash Flow | 70.0K | 921K | -86.0K | 1.13M | 2.76M | 3.61M | 1.12M | 390K | 1.86M | 895K |
| Ratios | ||||||||||
| ROE | - | - | 89.2% | 67.7% | 55.9% | 20.7% | -0.2% | 0.6% | 4.0% | -16.1% |
| ROA | 15.4% | 4.7% | 8.5% | 17.9% | 31.5% | 15.2% | -0.1% | 0.4% | 3.2% | -11.2% |
| Net Profit Margin | 5.0% | 1.6% | 3.4% | 7.8% | 12.6% | 6.8% | -0.1% | 0.2% | 1.5% | -6.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Integrated Biopharma Inc dividends
Integrated Biopharma Inc has not paid dividends in the last 10 fiscal years.
Who owns Integrated Biopharma Inc
- Insiders 69.12%
- Institutions 0.06%
- Public & others 30.82%
- Shares outstanding 31.1M
- Free float 7.20M
Integrated Biopharma Inc company profile
- Company name
- Integrated Biopharma Inc
- Ticker
- INBP.US
- Exchange
- USA Stocks
- Listed since
- Oct 29, 1996
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 134
- Fiscal year end
- June
- Address
- Building 15, Hillside, NJ, United States, 07205
- Phone
- 888 319 6962
- Website
- ir.ibiopharma.com
About Integrated Biopharma Inc
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical segment provides warehousing and fulfilment services; and distributes raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Integrated Biopharma Inc management
4- Ms. Riva Kay SheppardCo-CEO & Director · born 1967
- Ms. Christina KayCo-CEO & Director · born 1970
- Ms. Dina L. MasiSenior VP, CFO & Secretary · born 1961
- Mr. Jamie E. LeveyHead of Investor Relations